Israeli Biotech Kadimastem Merges with NLS Pharmaceutics
Categories: Corporate and M&A
Israeli biotechnology company Kadimastem Ltd. has completed its merger with Switzerland-based NLS Pharmaceutics AG, creating NewCelX, a newly combined biotech company now traded on NASDAQ.
The merger strengthens cross-border collaboration between Israeli innovation and the global life sciences capital markets, uniting Kadimastem’s stem-cell-based therapeutics with NLS’s neuroscience research and commercialization capabilities.
Pearl Cohen represented Kadimastem, with the transaction led by partners Ilan Gerzi, Oded Kadosh, Joel Stein, and Max Lindenfeld from the firm’s Capital Markets team in Israel and the U.S.
The newly merged company, NewCelX, is expected to advance cutting-edge therapies in biotechnology and life sciences.
